Latest Articles

Publication Date
All News Scientific
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial - Yahoo Finance

Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial Yahoo Finance

Published: July 27, 2026, 10:08 p.m.
Read Full Article
Psychology graduate’s research highlights impact of long waits for endometriosis diagnosis - Nation.Cymru

Psychology graduate’s research highlights impact of long waits for endometriosis diagnosis Nation.Cymru

Published: July 17, 2026, 6:45 a.m.
Read Full Article
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer - CancerNetwork

Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer CancerNetwork

Published: July 16, 2026, 3:40 p.m.
Read Full Article
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
What New MRI Research Reveals About Endometrial Cancer Staging and the 2023 FIGO Staging System - diagnosticimaging.com

What New MRI Research Reveals About Endometrial Cancer Staging and the 2023 FIGO Staging System diagnosticimaging.com

Published: July 1, 2026, 12:21 p.m.
Read Full Article
FAPI PET/MRI detects more endometriosis lesions than MRI alone - AuntMinnieEurope

FAPI PET/MRI detects more endometriosis lesions than MRI alone AuntMinnieEurope

Published: June 22, 2026, 9:16 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!